News Daily News FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy Michael O'Riordan April 29, 2022
News Daily News CVD Hospitalizations Spiked in Aftermath of 2020 US Election Michael O'Riordan April 22, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Guideline-Directed Therapies Underused in Frail HF Patients L.A. McKeown March 11, 2022
News Daily News Skipping Low-Value Cardiovascular Care Could Save Billions: AHA Michael O'Riordan March 01, 2022
News Daily News Financial Strain Ups Risk of Death After Acute MI in the Elderly L.A. McKeown February 25, 2022
News Daily News FDA Approves Empagliflozin for Treatment of HFpEF Michael O'Riordan February 24, 2022
News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022
News Daily News As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control Caitlin E. Cox January 10, 2022
News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Conference News AHA 2021 Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF Michael O'Riordan November 19, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021